XM does not provide services to residents of the United States of America.
C
C

Celanese

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

U.S. Coca-Cola, KB Home, Newmark Group

U.S. RESEARCH ROUNDUP-Coca-Cola, KB Home, Newmark Group Sept 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Coca-Cola, KB Home and Newmark Group on Thursday. HIGHLIGHTS * Capital Clean Energy Carriers CCEC.O : Evercore ISI initiates coverage with outperform rating * Coca-Cola Co KO.N : CFRA cuts to hold from buy * KB Home KBH.N : RBC cuts to underperform from sector perform * Newmark Group Inc NMRK.O : KBW raises
B
U
C
D
C
C
L

U.S. Airbnb, Dollar General, Walmart

U.S. RESEARCH ROUNDUP-Airbnb, Dollar General, Walmart Aug 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Airbnb, Dollar General and Walmart, on Monday. HIGHLIGHTS * Airbnb Inc ABNB.O : Jefferies cuts target price to $125 from $150 * Dollar General Corp DG.N : Jefferies cuts target price to $145 from $160 * Hilton Grand Vacations Inc HGV.N : JP Morgan cuts to neutral from overweight * Pacira Biosciences Inc PCRX.O
A
E
T
A
D
D
C
F

Celanese Underlying Supply Chain Conditions Behind Declaration Have Stabilized

BRIEF-Celanese Underlying Supply Chain Conditions Behind Declaration Have Stabilized Aug 8 (Reuters) - Celanese Corp CE.N : CELANESE CORPORATION LIFTS FORCE MAJEURE ON WESTERN HEMISPHERE ACETIC ACID AND VAM CELANESE CORP: UNDERLYING SUPPLY CHAIN CONDITIONS BEHIND DECLARATION HAVE STABILIZED Source text for Eikon: ID:nBw5Tt5YRa Further company cover
C

Celanese lifts force majeure condition for some products sold in western hemisphere

Celanese lifts force majeure condition for some products sold in western hemisphere Aug 8 (Reuters) - Specialty chemicals maker Celanese CE.N said on Thursday it had lifted the force majeure condition it invoked in the second quarter for its acetic acid and vinyl acetate monomer products sold in the western hemisphere after supply conditions improved.
C

U.S. Amphastar Pharmaceuticals, G1 Therapeutics, Upwork

U.S. RESEARCH ROUNDUP-Amphastar Pharmaceuticals, G1 Therapeutics, Upwork Aug 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amphastar Pharmaceuticals, G1 Therapeutics and Upwork on Thursday. HIGHLIGHTS * Amphastar Pharmaceuticals Inc AMPH.O : Piper Sandler cuts target price to $66 from $71 * Charles River Laboratories International Inc CRL.N : Baird cuts to neutral * G1 Therapeutics Inc GTHX.O : H.C.
A
A
C
G
A
C
I

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.